Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

2.94USD
16 Feb 2018
Change (% chg)

$0.09 (+3.16%)
Prev Close
$2.85
Open
$2.86
Day's High
$3.01
Day's Low
$2.85
Volume
10,664
Avg. Vol
15,811
52-wk High
$6.43
52-wk Low
$2.55

Latest Key Developments (Source: Significant Developments)

Cesca Therapeutics Announces Pricing Of Public Offering
Wednesday, 29 Nov 2017 09:07am EST 

Nov 29 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 900,000 SHARES OF COMMON STOCK.CESCA THERAPEUTICS INC - PRICED REGISTERED PUBLIC OFFERING AT $3.00 PER SHARE​.  Full Article

Cesca Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 28 Nov 2017 05:20pm EST 

Nov 28 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Cesca Therapeutics reports quarterly loss per share $0.24
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces financial results for the three months ended September 30, 2017 and provides corporate update.Quarterly loss per share $0.24.Quarterly revenue $3.1 million versus $3.8 million.  Full Article

Cesca Therapeutics ‍receives Notice of Allowance for U.S. patent application covering a novel method of cell separation​
Tuesday, 3 Oct 2017 07:00am EDT 

Oct 3 (Reuters) - Cesca Therapeutics Inc : :Cesca Therapeutics Inc - ‍receives Notice of Allowance for U.S. patent application covering a novel method of cell separation​.  Full Article

Cesca Therapeutics says co entered into Amendment No. 1 to Revolving Credit Agreement with Boyalife Investment Fund II​
Friday, 22 Sep 2017 06:52am EDT 

Sept 22 (Reuters) - Cesca Therapeutics Inc :Cesca Therapeutics - ‍on September 13, 2017, co entered into an Amendment No. 1 to Revolving Credit Agreement with Boyalife Investment Fund II, Inc​.Cesca Therapeutics - amendedment amends Revolving Credit Agreement entered on March 6, 2017, by increasing borrowing availability to $10.0 million​.Cesca Therapeutics - ‍in connection with amendment, co entered amended and restated convertible promissory note to reflect new amount of $10.0 million​.  Full Article

Cesca Therapeutics announces distribution agreement with Boyalife WSN
Thursday, 24 Aug 2017 11:09am EDT 

Aug 24 (Reuters) - Cesca Therapeutics Inc :Cesca Therapeutics announces international distribution agreement with Boyalife WSN Ltd..‍Agreement to market and distribute Cesca's biobanking and point-of-care solutions in China, India, Singapore and Philippines​.  Full Article

Cesca Therapeutics says acquires cell processing systems of SynGen
Monday, 10 Jul 2017 07:45am EDT 

July 10 (Reuters) - Cesca Therapeutics Inc :Cesca therapeutics acquires the cell processing systems of syngen under asset acquisition agreement.Cesca therapeutics inc - wholly-owned subsidiary, thermogenesis corp., has entered into an asset acquisition agreement with syngen inc.Cesca therapeutics inc- ‍wholly-owned subsidiary, thermogenesis corp., has entered into an asset acquisition agreement with syngen inc​.Cesca therapeutics inc- ‍representative of syngen's majority shareholder, bay city capital, has joined board of directors of themogenesis​.Cesca therapeutics - philip coelho, co-founder and cto of syngen, has joined thermogenesis in chief technology officer role, effective immediately.Cesca therapeutics inc- ‍in exchange for assets, thermogenesis granted syngen 20% of its common stock and paid a one-time cash payment of $1 million​.  Full Article

Cesca Therapeutics Q3 loss per share $0.21
Thursday, 11 May 2017 04:16pm EDT 

May 11 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces fiscal third quarter and nine month 2017 financial and operating results and provides corporate update.Q3 revenue $3.3 million versus $2.8 million.Q3 loss per share $0.21.  Full Article

Cesca Therapeutics announces closing of $5 mln revolving line of credit
Monday, 13 Mar 2017 06:00am EDT 

Cesca Therapeutics Inc - : Cesca Therapeutics announces closing of $5 million revolving line of credit . Has set-up a wholly-owned subsidiary, Thermogenesis Corp, to separately own and operate its device business . Clinical development activities will remain with cesca, parent company ."Our goal is to make thermogenesis cash-flow neutral within next 12 months".  Full Article

Cesca Therapeutics Q2 revenue rose 22 percent to $4.0 mln
Monday, 13 Feb 2017 04:05pm EST 

Cesca Therapeutics Inc : Cesca therapeutics reports second quarter fiscal 2017 financial results and provides business update . Q2 revenue rose 22 percent to $4.0 million .Says net loss was $3.4 million for three months ended december 31, 2016.  Full Article

BRIEF-Cesca Therapeutics Files For Common Stock Offering Of Up To $15 Mln

* FILES FOR COMMON STOCK OFFERING OF UP TO $15 MILLION - SEC FILING Source text: (http://bit.ly/2E1uKu2) Further company coverage: